Inoviq (ASX:IIQ) ROCE % : -40.88% (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Inoviq ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Inoviq's annualized ROCE % for the quarter that ended in Dec. 2023 was -40.88%.

Inoviq ROCE % Historical Data

The historical data trend for Inoviq's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inoviq ROCE % Chart

Inoviq Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-55.36

-42.38

-36.51

-29.49

-42.78

Inoviq Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-22.29	-24.81	-47.12	-39.57	-40.88

Inoviq ROCE % Calculation

Inoviq's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-10.476	/	( ( (30.779 - 1.796)	+	(21.509 - 1.518) )	/ 2 )
	=	-10.476	/	( (28.983	+	19.991)	/ 2 )
	=	-10.476	/	24.487
	=	-42.78 %

Inoviq's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-7.562	/	( ( (21.509 - 1.518)	+	(18.406 - 1.403) )	/ 2 )
	=	-7.562	/	( ( 19.991	+	17.003 )	/ 2 )
	=	-7.562	/	18.497
	=	-40.88 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Inoviq (ASX:IIQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Inoviq ROCE % Related Terms

Thank you for viewing the detailed overview of Inoviq's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inoviq (ASX:IIQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168

Website

https://www.bard1.com

Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Inoviq (ASX:IIQ) Headlines

No Headlines